New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2014
07:03 EDTTFXTeleflex reaffirms FY14 adjusted EPS view $5.35-$5.55, consensus $5.41
Reaffirms FY14 constant currency revenue growth between 7% and 9%, consensus $1.78B.
News For TFX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
10:02 EDTTFXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:46 EDTTFXTeleflex downgraded to Equal Weight from Overweight at Stephens
Subscribe for More Information
October 29, 2014
07:03 EDTTFXTeleflex ups FY14 adjusted EPS view to $5.60-$5.70 from $5.45-$5.60
FY14 EPS consensus $5.59. Ups FY14 constant currency revenue growth guidance to a range of 7.5%-9% from a range of 7%-9%, consensus $1.84B.
07:01 EDTTFXTeleflex reports Q3 adjusted EPS $1.57, consensus $1.37
Reports Q3 revenue $457.2M, consensus $447.93M.
October 28, 2014
07:14 EDTTFXTeleflex awarded U.S. Army grant to develop anti-biofilm orthopedic device
Teleflex Incorporated has been awarded a $2.1M research grant from the U.S. Army’s Telemedicine and Advanced Technology Research Center, located at Fort Detrick, MD. The award will support research and development of a surface-modified tibial intramedullary nail that combines the Semprus Sustain technology with antimicrobial technology. Up to an additional $2.46M in funding for the project may be provided under the award, at the U.S. Army’s discretion. The research will be conducted at Teleflex’s facilities in Cambridge, MA, in conjunction with U.S. Army Institute for Surgical Research at Fort Sam Houston in San Antonio, TX. This award builds upon an initial $1.1M TATRC grant awarded to Semprus BioSciences in 2011 to develop the world’s first orthopedic devices designed to reduce biofilm formation.
October 20, 2014
07:20 EDTTFXInternational Continence Society to hold annual meeting
ICS Annual Meeting 2014 is being held in Rio de Janeiro, Brazil on October 20-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use